Integra LifeSciences (NASDAQ:IART) Shares Gap Down - Time to Sell?

Key Points

• Integra LifeSciences shares fell 18.7%, opening at $13.31 versus a prior close of $16.09, with the latest trade near $13.63.
• Analyst sentiment remains cautious: the stock has an average “Reduce” rating, with five Holds, two Sells, and one Buy; the consensus price target is $18.86.
• The company beat quarterly EPS and revenue estimates, reporting $0.56 EPS on $418.76 million in revenue, while maintaining full-year 2026 EPS guidance of $2.40–$2.50.

Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report) shares gapped down before the market opened on Friday. The stock had previously closed at $16.09, but opened at $13.31. Integra LifeSciences shares last traded at $13.6270, with a volume of 130,662 shares trading hands.

Analyst Ratings Changes

A number of research firms recently issued reports on IART. Wells Fargo & Company increased their price target on shares of Integra LifeSciences from $15.00 to $18.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 30th. UBS Group began coverage on Integra LifeSciences in a research report on Tuesday, July 28th. They set a "neutral" rating and a $19.00 price objective on the stock. Citigroup reaffirmed a "neutral" rating and issued a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research note on Wednesday, July 8th. Truist Financial upgraded shares of Integra LifeSciences to a "hold" rating in a research note on Thursday. Finally, Argus raised shares of Integra LifeSciences from a "hold" rating to a "buy" rating and set a $25.00 price objective on the stock in a research note on Thursday, June 18th. One investment analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Reduce" and a consensus target price of $18.86.

Integra LifeSciences Trading Down 18.7%

The stock has a market cap of $1.02 billion, a PE ratio of -145.66, a PEG ratio of 0.84 and a beta of 1.21. The company has a quick ratio of 2.11, a current ratio of 3.60 and a debt-to-equity ratio of 1.75. The stock's fifty day moving average price is $16.83 and its 200 day moving average price is $15.17.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.The business had revenue of $418.76 million for the quarter, compared to analysts' expectations of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, sell-side analysts forecast that Integra LifeSciences Holdings Corporation will post 2.46 EPS for the current year.

Institutional Trading of Integra LifeSciences

A number of large investors have recently made changes to their positions in IART. Paradigm Capital Management Inc. NY boosted its holdings in Integra LifeSciences by 50.6% in the first quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company's stock worth $37,800,000 after purchasing an additional 1,347,700 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Integra LifeSciences by 12.4% during the 2nd quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company's stock valued at $26,241,000 after buying an additional 160,814 shares during the period. Bank of America Corp DE boosted its stake in shares of Integra LifeSciences by 71.4% in the 1st quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company's stock worth $13,325,000 after buying an additional 589,408 shares during the last quarter. Invenomic Capital Management LP boosted its stake in shares of Integra LifeSciences by 78.3% in the 4th quarter. Invenomic Capital Management LP now owns 1,055,941 shares of the life sciences company's stock worth $13,115,000 after buying an additional 463,729 shares during the last quarter. Finally, Glenmede Trust Co. NA grew its holdings in shares of Integra LifeSciences by 27.4% in the first quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company's stock worth $9,276,000 after acquiring an additional 211,774 shares during the period. 84.78% of the stock is currently owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation NASDAQ: IART is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company's products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.